Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DMOYS1N)

Drug Name

NT219 Drug Info

Synonyms

UNII-K1WT1A1UP5; K1WT1A1UP5; 1198078-60-2; (E)-3-(2-Bromo-3,4-dihydroxyphenyl)-N-(3,4,5-trihydroxybenzyl)prop-2-enethioamide; CHEMBL3679680; SCHEMBL12659248; BDBM101913; NT-219; US8536227, 5; 2-Propenethioamide, 3-(2-bromo-3,4-dihydroxyphenyl)-N-((3,4,5-trihydroxyphenyl)methyl)-; 2-Propenethioamide, 3-(2-bromo-3,4-dihydroxyphenyl)-N-((3,4,5-trihydroxyphenyl)methyl)-, (2E)-

Indication

Disease Entry	ICD 11	Status	REF
Solid tumour/cancer	2A00-2F9Z	Phase 1/2	[1]

Cross-matching ID

PubChem CID: 135914977
CAS Number: CAS 1198078-60-2
TTD Drug ID: DMOYS1N

Molecule-Related Drug Atlas

Molecule Type:

DTT

Drug Status:

Approved Drug(s)

Clinical Trial Drug(s)

Download the Complete Related Drug List

Drug(s) Targeting Signal transducer and activator of transcription 3 (STAT3)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Acitretin	DM8BKU9	Psoriasis vulgaris	EA90	Approved	[3]
Napabucasin	DMDZ6Q3	Colorectal cancer	2B91.Z	Phase 3	[4]
Golotimod	DMKZN3A	Immune System disease	4A01-4B41	Phase 2	[5]
WP-1066	DMUGHWR	Recurrent glioblastoma	2A00.00	Phase 1/2	[4]
Atiprimod	DM84YEC	Multiple myeloma	2A83	Phase 1/2	[6]
OPB-31121	DM6VGO3	Hepatocellular carcinoma	2C12.02	Phase 1/2	[7]
IMX-110	DMNHZS4	Solid tumour/cancer	2A00-2F9Z	Phase 1/2	[4]
GLG-801	DMY1CP9	Chronic lymphocytic leukaemia	2A82.0	Phase 1/2	[4]
OPB-51602	DM760FA	Solid tumour/cancer	2A00-2F9Z	Phase 1	[8]
TAK-114	DMTXE19	Ulcerative colitis	DD71	Phase 1	[9]
------------------------------------------------------------------------------------


⏷ Show the Full List of 10 Drug(s)

Molecular Interaction Atlas of This Drug

Molecular Interaction Atlas

Download the Complete Interaction Atlas for Visualization in Cytoscape

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
Insulin receptor substrate 2 (IRS2)	TTF95B8	IRS2_HUMAN	Inhibitor	[2]
Insulin receptor substrate-1 (IRS1)	TTADRX7	IRS1_HUMAN	Inhibitor	[2]
Signal transducer and activator of transcription 3 (STAT3)	TTH8FZW	STAT3_HUMAN	Inhibitor	[2]

------------------------------------------------------------------------------------

References

1	ClinicalTrials.gov (NCT04474470) A Study to Evaluate NT219 Alone and in Combination With ERBITUX (Cetuximab) in Adults With Advanced Solid Tumors and Head and Neck Cancer. U.S. National Institutes of Health.
2	Clinical pipeline report, company report or official report of Purple Biotech.
3	Effects of acitretin on the expression of signaling pathway-related genes in epidermal squamous-cell carcinoma cells. Zhonghua Zhong Liu Za Zhi. 2006 Jan;28(1):21-4.
4	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
5	National Cancer Institute Drug Dictionary (drug id 617379).
6	Emerging therapies for multiple myeloma. Expert Opin Emerg Drugs. 2009 Mar;14(1):99-127.
7	OPB-31121, a novel small molecular inhibitor, disrupts the JAK2/STAT3 pathway and exhibits an antitumor activity in gastric cancer cells. Cancer Lett. 2013 Jul 10;335(1):145-52.
8	Phase I and biomarker study of OPB-51602, a novel signal transducer and activator of transcription (STAT) 3 inhibitor, in patients with refractory solid malignancies. Ann Oncol. 2015 May;26(5):998-1005.
9	Clinical pipeline report, company report or official report of Gastroenterology.